Reply to: Graefe-Mody U, Friedrich C, Port A et al. Effect of renal impairment on the pharmacokinetics of the dipeptidyl peptidase-4 inhibitor linagliptin. Diabetes Obes Metab 2011; 13: 939-946
- PMID: 22651136
- DOI: 10.1111/j.1463-1326.2012.01588.x
Reply to: Graefe-Mody U, Friedrich C, Port A et al. Effect of renal impairment on the pharmacokinetics of the dipeptidyl peptidase-4 inhibitor linagliptin. Diabetes Obes Metab 2011; 13: 939-946
Comment on
-
Effect of renal impairment on the pharmacokinetics of the dipeptidyl peptidase-4 inhibitor linagliptin(*).Diabetes Obes Metab. 2011 Oct;13(10):939-46. doi: 10.1111/j.1463-1326.2011.01458.x. Diabetes Obes Metab. 2011. PMID: 21672124
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
